Jatin Kadakia, MD
Pulmonary Disease · Clarksville, TNNPI 1831262385
Payments from drug & device makers
Across 695 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Grifols USA, LLC$1K
- Regeneron Healthcare Solutions, Inc.$965
- Actelion Pharmaceuticals US, Inc.$938
- Mylan Specialty L.p.$924
- plus $5K from 32 others
What the payments were for
- Food & beverage$13,72597%
- Education$4373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 121 | $2,808 |
| GSK | 141 | $2,650 |
| Grifols USA, LLC | 60 | $1,080 |
| Regeneron Healthcare Solutions, Inc. | 51 | $965 |
| Actelion Pharmaceuticals US, Inc. | 42 | $938 |
| Mylan Specialty L.p. | 60 | $924 |
| Boehringer Ingelheim | 31 | $620 |
| Harmony Biosciences LLC | 16 | $569 |
| Sanofi | 25 | $514 |
| Insmed, Inc. | 25 | $432 |
| Jazz Pharmaceuticals Inc. | 12 | $374 |
| Viatris Specialty LLC | 12 | $248 |
| Verona Pharma, Inc. | 12 | $247 |
| Philips North America LLC | 15 | $227 |
| Inspire Medical Systems, Inc. | 4 | $208 |
| Electromed, Inc. | 11 | $177 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $176 |
| Pfizer | 5 | $102 |
| Baxter Healthcare | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Pulmonx Corporation | 3 | $72 |
| Circassia Inc. | 4 | $71 |
| Genentech USA, Inc. | 4 | $67 |
| Sanofi-aventis U.S. LLC | 1 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Advanced Respiratory, Inc | 3 | $50 |
| United Therapeutics Corporation | 2 | $38 |
| Novartis | 2 | $37 |
| Bayer | 1 | $30 |
| Eisai Inc. | 2 | $27 |
| La Jolla Pharmaceutical Company | 1 | $27 |
| Amgen | 1 | $25 |
| 3b Medical, Inc. | 1 | $25 |
| Breas Medical, Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,162 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 341 | $299,514 |
| OpsumitMacitentan | 13 | $164,493 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $82,646 |
| Ambrisentan | 14 | $39,900 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $32,403 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $29,204 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $23,436 |
| Spiriva RespimatTiotropium Bromide | 38 | $22,559 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 64 | $13,493 |
| JardianceEmpagliflozin | 14 | $12,464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 242 | $9,882 |
| Arnuity ElliptaFluticasone Furoate | 21 | $8,398 |
| EliquisApixaban | 11 | $6,976 |
| Tiotropium Bromide | 12 | $6,331 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 15 | $4,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,650 | $369,519448 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $938 | $164,49313 claims |
| AstraZenecaBreztri Aerosphere | $2,808 | $82,646104 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $620 | $35,02352 claims |
| PfizerEliquis, Abrysvo | $102 | $11,79326 claims |
| Eisai Inc.Dayvigo | $27 | $3,62414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Clarksville
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.